Do SGLT2 inhibitors reduce atrial and ventricular arrhythmic events in HFrEF patients with an ICD or CRT-D?
SGLT2 inhibitors may provide antiarrhythmic benefits by significantly reducing atrial and ventricular arrhythmic events in patients with HFrEF and implantable defibrillators.
In HFrEF carriers of ICD/CRT-D, the use of SGLT2i resulted in significant reduction of AA and VA events.
Mariani et al. (2025) studied this question.